Articles tagged with “real-world-evidence”

Examine clinical evidence generation for AI diagnostic SaMD. This report covers real-world performance studies, FDA guidelines, and post-market surveillance.

Learn how pharma companies build regulatory-grade real-world evidence (RWE) platforms using real-world data for FDA and EMA drug development submissions.

Learn about value-based contracting (VBC) in pharma. Our guide covers how these agreements tie drug reimbursement to patient outcomes, key data requirements, an

Efficacy in clinical trials often overstates real-world effectiveness. Learn why this gap exists and how HEOR uses real-world evidence (RWE) to correct for it.

Learn about outcomes-based drug reimbursement contracts. This article explains the complex IT systems & data infrastructure needed to track real-world patient o

Learn how AI and machine learning analyze Real-World Data (RWD) to generate Real-World Evidence (RWE). Explore key applications including LLM-driven data extraction, pharmacovigilance, and synthetic control arms, plus 2025-2026 FDA and EMA regulatory updates.

Explore the state of Real-World Evidence (RWE) analysis in 2025-2026. This guide covers RWD sources, analytical methods, FDA/EMA regulatory frameworks, ICH E6(R3), synthetic control arms, AI-driven RWE platforms, and compares RWE with RCTs

Get a detailed guide to Oracle Life Sciences solutions. Learn about key products for clinical trials (Clinical One 26.1), pharmacovigilance (Argus Safety), Health Data Intelligence, and AI-powered analytics.

Explore a technical blueprint for an RWE platform architecture, detailing how to integrate real-world data (RWD) from EMR, claims, and genomics sources. Updated with 2025-2026 developments including EHDS regulation, DARWIN EU progress, and FHIR R5.

Learn how target trial emulation provides a structured framework for drawing causal inference from real-world evidence (RWE), with 2025 updates on the TARGET reporting guideline, ICH M14, and FDA guidance.

An overview of value-based contracting (VBC) in pharmaceuticals, where drug prices are tied to patient outcomes. Covers models, challenges, case studies, CMS CGT Access Model (2025), finalized VBP rule (2026), and IRA drug price negotiations.

A detailed overview of IQVIA's technology solutions for life sciences, updated for 2026. Covers data management, OCE-to-Salesforce Life Sciences Cloud transition, AI agents with NVIDIA, analytics platforms, and RWE.

This article details AI applications in pharmaceutical business intelligence, covering drug discovery, clinical trials, supply chain, real-world evidence, and market intelligence.

Learn how Power BI consultants apply business intelligence to pharmaceutical data, addressing regulatory needs, clinical trial insights, and RWE analysis.

An in-depth analysis of how artificial intelligence is transforming clinical data management across US healthcare, from EHR documentation to clinical trials and real-world evidence.

Comprehensive overview of Oracle's role in the pharmaceutical industry, covering their Health Sciences solutions, cloud infrastructure, compliance features, and case studies of successful implementations at major pharma companies.

Practical guide for Market Access teams and field representatives on handling common payer objections in oncology, including strategies for verbal and written communications, real-world examples, and response frameworks.

A comprehensive guide to the leading commercial analytics software platforms for pharmaceutical companies, covering sales forecasting, field force effectiveness, market access analysis, real-world evidence integration, customer segmentation, and omnichannel marketing optimization.